Резултати

eNauka >  Results >  Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Naziv: Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301
Autori: Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A.; Reungwetwattana, Thanyanan; Yang, James Chih-Hsin; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun;
Godina: 2023
Publikacija: Journal of Clinical Oncology
ISSN: 0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 41 br. 26 str. 4208-4217
DOI: 10.1200/JCO.23.00515
WoS-ID: 001069556400005
Scopus-ID: 2-s2.0-85170112349
PMID: 37379502
URI: https://enauka.gov.rs/handle/123456789/933671
Projekat: The authors would like to thank all the patients who participated in this study and their families and caregivers. The authors would also like to thank the physicians and nurses who cared for the patients and the staff at the clinical sites.
Izvor metapodataka: (Preuzeto iz CrossRef-a) Zarić, Bojan
(Preuzeto iz Nasi u WoS)
M-kategorija: 
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

147
SCOPUSTM
61
PubMed CentralTM
6
OpenCitations
135
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.